Allergan said on Nov. 1 that it planned to begin selling its Teva stake, and this …
Taking a quick step back, AGN is up 1.6% at $210.53. This week's collective momentum represents quite the respite for the drug stock, which is among the worst performers on the S&P 500 Index (SPX) in 2016, down close to 33% year-to …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. Allergan plc (NYSE: AGN) announced that the Company's board …
ERISA imposes fiduciary duties to prudently manage and invest plan assets. We are investigating whether these duties …
Allergan, Inc. (NYSE:AGN) has piled more fuel on the fire as it tries to battle the hostile offer from Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The Botox maker sharply increased its full year and third quarter earnings …
... sent out its official tender offer to Allergan Inc. /quotes/zigman/217110/delayed /quotes/nls/agn AGN shareholders Wednesday. The cash-and-stock offer, which now stands at $72 in cash and 0.83 shares of Valeant for every share of …
But as David Gelles reported for the New York Times in June, Goldman has been unusually quiet in the Allergan battle, and for an unusual reason: In June 2013, Goldman was the sole underwriter on a $2.3 billion Valeant stock offering to …
The developments came a day after Allergan tried to discredit Valeant by attacking its business model and stock price. Allergan claimed Valeant had overstated its organic growth rates and pro forma revenue growth. Mr. Pearson, a …
Shares of Allergan Inc. fell sharply Wednesday after the Irvine-based pharmaceutical company said it would delay final testing on two of the most promising drugs in its pipeline. The company’s CEO, David Pyott, told analysts and …